Standard BioTools (LAB) Competitors

Standard BioTools (NASDAQ:LAB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.

Which has more volatility & risk, LAB or TXG?

Standard BioTools has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.

Does the media favor LAB or TXG?

In the previous week, 10x Genomics had 18 more articles in the media than Standard BioTools. MarketBeat recorded 19 mentions for 10x Genomics and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.67 beat 10x Genomics' score of 0.75 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
10x Genomics	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Is LAB or TXG more profitable?

10x Genomics has a net margin of -29.90% compared to Standard BioTools' net margin of -79.92%. 10x Genomics' return on equity of -25.40% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	-79.92%	-27.05%	-15.52%
10x Genomics	-29.90%	-25.40%	-19.69%

Do institutionals and insiders believe in LAB or TXG?

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by insiders. Comparatively, 9.4% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend LAB or TXG?

Standard BioTools presently has a consensus target price of $2.50, suggesting a potential upside of 138.10%. 10x Genomics has a consensus target price of $15.81, suggesting a potential upside of 74.09%. Given Standard BioTools' stronger consensus rating and higher possible upside, equities analysts clearly believe Standard BioTools is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
10x Genomics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

Which has higher valuation and earnings, LAB or TXG?

Standard BioTools has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$169.69M	2.35	-$74.66M	-$0.35	-3.00
10x Genomics	$624.66M	1.78	-$182.63M	-$1.30	-6.98

Does the MarketBeat Community favor LAB or TXG?

10x Genomics received 60 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 83.33% of users gave Standard BioTools an outperform vote while only 50.39% of users gave 10x Genomics an outperform vote.

Company	Underperform	Outperform
Standard BioTools	Outperform Votes 5 83.33%	Underperform Votes 1 16.67%
10x Genomics	Outperform Votes 65 50.39%	Underperform Votes 64 49.61%

Summary

Standard BioTools beats 10x Genomics on 10 of the 18 factors compared between the two stocks.